IMVT-1402

Immunovant's batoclimab demonstrated statistically significant improvement in myasthenia gravis symptoms in Phase III trial, with high-dose patients showing a 5.6-point improvement on the MG-ADL scale versus 3.6 points for placebo.

Batoclimab, an anti-FcRn antibody developed by HanAll Biopharma, has received Orphan Drug Designation from Japan's MHLW for active Thyroid Eye Disease, a rare condition affecting approximately 35,000 Japanese patients.

Immunovant is poised to release crucial Phase 3 trial results for batoclimab in generalized myasthenia gravis by March end, with analysts maintaining a Buy rating and $50 price target.

The global rheumatoid arthritis market is projected to grow from $28 billion in 2024 to $34.7 billion by 2035, with a CAGR of 1.97%, fueled by advancements in biologics and targeted therapies.

Immunovant's IMVT-1402 receives five IND clearances across various therapeutic areas, paving the way for registrational trials.